Free Trial

Perrigo (PRGO) Competitors

Perrigo logo
$27.91 -0.16 (-0.57%)
As of 02:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PRGO vs. CORT, JAZZ, SUPN, PCRX, NKTR, OMER, ASMB, CPIX, LLY, and JNJ

Should you be buying Perrigo stock or one of its competitors? The main competitors of Perrigo include Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceuticals" industry.

Perrigo vs. Its Competitors

Perrigo (NYSE:PRGO) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

Corcept Therapeutics has a net margin of 19.33% compared to Perrigo's net margin of -4.16%. Corcept Therapeutics' return on equity of 20.40% beat Perrigo's return on equity.

Company Net Margins Return on Equity Return on Assets
Perrigo-4.16% 8.93% 3.87%
Corcept Therapeutics 19.33%20.40%16.64%

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 0.4% of Perrigo shares are owned by insiders. Comparatively, 20.5% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Perrigo presently has a consensus price target of $33.00, indicating a potential upside of 18.24%. Corcept Therapeutics has a consensus price target of $138.25, indicating a potential upside of 99.70%. Given Corcept Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Perrigo.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Perrigo
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.25
Corcept Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Corcept Therapeutics had 11 more articles in the media than Perrigo. MarketBeat recorded 21 mentions for Corcept Therapeutics and 10 mentions for Perrigo. Corcept Therapeutics' average media sentiment score of 1.00 beat Perrigo's score of 0.86 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Perrigo
5 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Corcept Therapeutics
10 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Perrigo has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500.

Corcept Therapeutics has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Perrigo$4.37B0.88-$171.80M-$1.31-21.31
Corcept Therapeutics$675.04M10.88$141.21M$1.1659.68

Summary

Corcept Therapeutics beats Perrigo on 13 of the 16 factors compared between the two stocks.

Get Perrigo News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRGO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRGO vs. The Competition

MetricPerrigoMED PRODUCTS IndustryMedical SectorNYSE Exchange
Market Cap$3.84B$10.44B$5.61B$20.89B
Dividend Yield4.12%1.91%4.71%3.60%
P/E Ratio-21.3116.9527.9028.01
Price / Sales0.8828.86392.4668.85
Price / Cash5.5723.3936.3223.29
Price / Book0.883.668.394.56
Net Income-$171.80M$234.77M$3.25B$993.24M
7 Day Performance-0.73%-1.82%-1.61%-1.58%
1 Month Performance4.41%5.56%9.08%3.09%
1 Year Performance-1.34%-13.62%35.49%9.26%

Perrigo Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRGO
Perrigo
4.5303 of 5 stars
$27.91
-0.6%
$33.00
+18.2%
+0.4%$3.84B$4.37B-21.318,379Upcoming Earnings
CORT
Corcept Therapeutics
4.8211 of 5 stars
$70.12
-1.0%
$138.25
+97.2%
+86.7%$7.44B$675.04M60.45300Positive News
Upcoming Earnings
JAZZ
Jazz Pharmaceuticals
4.8181 of 5 stars
$112.65
-0.2%
$181.71
+61.3%
+4.9%$6.82B$4.07B15.022,800Positive News
Upcoming Earnings
SUPN
Supernus Pharmaceuticals
2.585 of 5 stars
$33.23
+2.8%
$36.00
+8.3%
+9.3%$1.81B$668.00M29.94580News Coverage
Positive News
Upcoming Earnings
Analyst Upgrade
Gap Up
PCRX
Pacira BioSciences
3.2513 of 5 stars
$22.17
+2.7%
$26.44
+19.3%
+6.2%$1.03B$700.97M-9.72720
NKTR
Nektar Therapeutics
4.0778 of 5 stars
$24.79
-0.6%
$88.33
+256.3%
+12.3%$307.64M$98.43M-2.58220News Coverage
Positive News
Upcoming Earnings
OMER
Omeros
3.7698 of 5 stars
$3.64
+8.3%
$18.00
+394.5%
-26.2%$213.27MN/A-1.37210Positive News
Upcoming Earnings
ASMB
Assembly Biosciences
3.7987 of 5 stars
$18.25
-2.3%
$33.00
+80.8%
+26.4%$139.43M$28.52M-2.93100Upcoming Earnings
CPIX
Cumberland Pharmaceuticals
0.8895 of 5 stars
$3.50
+8.7%
N/A+144.1%$52.36M$37.87M-14.0080Upcoming Earnings
LLY
Eli Lilly and Company
4.9836 of 5 stars
$762.22
-1.2%
$1,012.56
+32.8%
-5.5%$722.39B$49.00B62.0247,000Trending News
JNJ
Johnson & Johnson
4.8287 of 5 stars
$164.38
+0.4%
$172.87
+5.2%
+6.0%$395.51B$90.63B17.58138,100Positive News
Analyst Revision

Related Companies and Tools


This page (NYSE:PRGO) was last updated on 7/30/2025 by MarketBeat.com Staff
From Our Partners